May 27, 2020
Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)
Jul 12, 2019
Arzerra Drug Overview 2019: A Fully Human Immunoglobulin G1 and High-Affinity Antibody that Targets a Novel Epitope on Cluster of Differentiation 20 (CD20) on the B-Cell Membrane
Jul 08, 2019
Copiktra (Duvelisib; Verastem/Yakult Honsha) Drug Overview & Product Profiles 2017-2026
Jun 03, 2019
IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
Oct 04, 2018
Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy
Mar 26, 2018
Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Mar 21, 2018
Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018
Dec 09, 2017
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
Jun 05, 2017
Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up